Skip to content

MR Fingerprinting: A Novel Sequence Applied to Neuroimaging

MR Fingerprinting: A Novel Sequence Applied to Neuroimaging

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03800537
Enrollment
14
Registered
2019-01-11
Start date
2019-03-08
Completion date
2022-08-18
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disease;Neurological

Brief summary

Magnetic Resonance Imaging (MRI) has become one of most important medical imaging tools over the past 30 years because it is non-invasive, requires no ionizing radiation, and provides exquisite images of soft tissues and anatomic structures with many tissue/disease specific contrasts. While MRI has served the community well for many years, it is increasingly clear that it also has significant limitations. One of the principle limitations is the lack of quantitative information for tissue/structure characterization. The current paradigm of MRI is to use a set of scanner settings to generate an image weighted by a specific MR contrast mechanism (physical parameter), where it is hoped that variations in the parameter will be accentuated. However, without quantitative knowledge of the parameters, the final image contrast may depend on many factors, which complicates image interpretation and diagnostic performance. Quantitative measurement can provide a great deal of information about tissue properties and pathological conditions, since these parameters ultimately determine the contrast that is observed in conventional images.

Detailed description

The purpose of this study is to evaluate novel quantitative MRI techniques in clinical studies to determine whether they can provide better, faster and more useful information for clinical diagnosis. Quantitative MRI has been a continuous interest in the MRI community, but extremely challenging due to long acquisition times and sensitivity to motion. Recently, the investigators have introduced a novel MRI data acquisition approach, namely MR Fingerprinting (MRF), for simultaneous measurement of several important parameters in a single MRI scan. In this study, the investigators propose to apply MR Fingerprinting at UNC and evaluate its performance for different neurological diseases. The investigators hypothesize that the quantitative MR imaging technique will lead to improved tissue characterization and diagnosis.

Interventions

The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.

Sponsors

University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* The study will include English-speaking patients that are already scheduled to undergo a clinical neurological MRI for diagnostic purposes.

Exclusion criteria

* Pregnant women will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Percent of Participants With Visible Region of Interest (Imaging Visibility)Immediately following MRI completion, within approximately 5 minutesMagnetic Resonance (MR) fingerprinting sequences will be examined to determine their utility for visualizing pathology.

Countries

United States

Participant flow

Participants by arm

ArmCount
All Participants
All participants will receive the investigational MR Fingerprinting sequence. MR Fingerprinting: The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
14
Total14

Baseline characteristics

CharacteristicAll Participants
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
2 Participants
Age, Categorical
Between 18 and 65 years
12 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
14 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
4 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
10 Participants
Region of Enrollment
United States
14 Participants
Sex: Female, Male
Female
11 Participants
Sex: Female, Male
Male
3 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 14
other
Total, other adverse events
0 / 14
serious
Total, serious adverse events
0 / 14

Outcome results

Primary

Percent of Participants With Visible Region of Interest (Imaging Visibility)

Magnetic Resonance (MR) fingerprinting sequences will be examined to determine their utility for visualizing pathology.

Time frame: Immediately following MRI completion, within approximately 5 minutes

ArmMeasureValue (NUMBER)
All ParticipantsPercent of Participants With Visible Region of Interest (Imaging Visibility)100 percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026